SNSE: Sensei Bio Net earnings per share (EPS TTM)

Sensei Biotherapeutics, Inc. (SNSE) - corporate logo

The development of the Immuno-Phage platform by Sensei Biotherapeutics (SNSE) is independent of economic cycles, as demonstrated by the trailing 12-month net income per share. The level of -18.97 represents the current value of this metric. Fundamentally, the business relies on capital raising due to a lack of sales and the risks of clinical antibody test failures, leaving the company dependent on new equity offerings.

SNSE Sensei Biotherapeutics Net earnings per share for the last 12 months (07/04/2022 - 06/16/2026)

Summary analytical data breakdowns for Sensei Biotherapeutics (SNSE)

- share price and expert price forecast:
Stock Quotes Sensei Biotherapeutics, Inc.|SNSE - Fair Value Consensus
- market capitalization information:
Market Capitalization Sensei Biotherapeutics|SNSE - Company Buyout Price
- business book valuation details:
Net Assets per Single Share Sensei Biotherapeutics|SNSE - Company Net Assets|Market Value to Book Value Ratio senseibio.com|SNSE - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Sensei Biotherapeutics|SNSE - Long-Term Debt to Capital|Short-Term Debt to Equity Sensei Biotherapeutics Inc|SNSE - Company Aggregate Debt|Debt to Book Capitalization Ratio Sensei Biotherapeutics, Inc.|SNSE - Long-Term Debt|Company Current Liabilities Sensei Biotherapeutics|Quick Liquidity Indicator senseibio.com
- earnings and multiples data:
SNSE - Profit After Payment of Taxes|Projected Future Earnings Sensei Biotherapeutics|SNSE - Company Value to Net Income|Forward P/E Multiple Sensei Bio|SNSE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SNSE|SNSE - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Sensei Biotherapeutics|SNSE - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months senseibio.com|SNSE - Earnings per share trend in current year|Expected earnings per share growth for next year Sensei Biotherapeutics
- revenue and sales details:
SNSE - Company Total Revenue|Company Projected Revenue Sensei Biotherapeutics Inc|SNSE - Price-to-Revenue Coefficient|Forward P/S Multiple Sensei Biotherapeutics, Inc.
Fundamental valuation:SNSE - senseibio.com
Flagship merchandise of Sensei Bio

Sensei Biotherapeutics (SNSE) operates as a small-cap biotech with minimal environmental impact, focusing on laboratory research. The specific nature of the clinical trial stage results in a lack of large-scale revenues, which directly impacts the calculation of net income distributed per share. This trailing twelve-month (TTM) metric measures the final business efficiency, adjusted for the volume of issuance. By analyzing the TTM earnings per share (EPS), an investor assesses the financial stability of Sensei Biotherapeutics (SNSE) during periods of market volatility. The TTM EPS trend allows for the identification of the model's adaptability to development costs.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)